__NUXT_JSONP__("/drugs/Lutetium_Lu_177__Vipivotide_Tetraxetan", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1703749-62-5",chebiId:b,chemicalFormula:b,definition:"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.",fdaUniiCode:"G6UF363ECX",identifier:"C148145",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129819","C2124"],synonyms:["177Lu-PSMA-617","177Lu-labeled PSMA-617","LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","Lu177-PSMA-617",c,"Lutetium Lu 177-PSMA-617"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLutetium_Lu_177__Vipivotide_Tetraxetan",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Lutetium_Lu_177__Vipivotide_Tetraxetan","","Lutetium Lu 177  Vipivotide Tetraxetan","2021-10-30T13:33:08.593Z")));